类淀粉沉积症药物市场规模、份额、成长分析（按治疗类型、给药途径、应用、最终用户、分销管道和地区）- 2025 年至 2032 年行业预测

预计 2023 年全球类淀粉沉积症药物市场价值将达到 201 亿美元，从 2024 年的 228.5 亿美元增长到 2032 年的 638.3 亿美元，预测期内（2025-2032 年）的复合年增长率为 13.7%。

全球类淀粉沉积症治疗市场正经历强劲成长，这得益于类淀粉沉积症盛行率的提高和认知度的提高，以及临床实践和诊断技术的重大进步。创新的标靶治疗正在获得认可，从而推动了对安宁疗护解决方案的需求。人口老化，尤其是越来越多的具有遗传倾向的人群，正在促进市场扩张，而有利的政府政策和孤儿药激励措施正在推动治疗药物的采用。医疗保健专业人员和患者意识的提高有助于早期发现症状。此外，人工智慧、机器学习、物联网和扩增实境等技术的融合正在彻底改变药物发现、精准医疗、病患监测和诊断影像，最终改善类淀粉沉积症治疗的治疗效果和法规遵循。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术评估
• 监管格局
• 客户和购买标准分析
• 管道分析
• 疾病流行病学

类淀粉沉积症药物市场规模（依治疗类型及复合年增长率）（2025-2032）

• 市场概况
• 化疗
• 干细胞移植
• 标靶治疗
• 支持性治疗和手术
• 其他的

类淀粉沉积症药物市场规模（依给药途径及复合年增长率）（2025-2032）

• 市场概况
• 口服
• 静脉
• 皮下

类淀粉沉积症药物市场规模（按应用和复合年增长率）（2025-2032）

• 市场概况
• AL类淀粉沉积症
• ATTR类淀粉沉积症
• AA类淀粉沉积症
• 野生型 ATTR

类淀粉沉积症药物市场规模（依最终用户和复合年增长率）(2025-2032)

• 市场概况
• 医院和诊所
• 门诊手术中心
• 居家照护环境
• 其他的

类淀粉沉积症药物市场规模（按分销管道和复合年增长率）（2025-2032）

• 市场概况
• 医院药房
• 零售药局
• 在线的

类淀粉沉积症药物市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 按部门分類的公司份额分析
  • 收益同比比较（2022-2024 年）

主要企业简介

• Pfizer Inc.（USA）
• Alnylam Pharmaceuticals（USA）
• Ionis Pharmaceuticals（USA）
• AstraZeneca（UK）
• Johnson & Johnson（USA）
• Novo Nordisk A/S（Denmark）
• BridgeBio Pharma（USA）
• Prothena Corporation（Ireland）
• Alexion Pharmaceuticals（USA）
• Takeda Pharmaceutical Company（Japan）
• Attralus（USA）
• Caelum Biosciences（USA）
• Zentalis Pharmaceuticals（USA）
• GlaxoSmithKline plc（GSK）（UK）
• Intellia Therapeutics（USA）
• Sanofi（France）
• F. Hoffmann-La Roche（Switzerland）
• Akcea Therapeutics（USA）
• Bristol-Myers Squibb Company（USA）
• Regeneron Pharmaceuticals（USA）

结论和建议

Global Amyloidosis Therapeutics Market size was valued at USD 20.1 billion in 2023 and is poised to grow from USD 22.85 billion in 2024 to USD 63.83 billion by 2032, growing at a CAGR of 13.7% during the forecast period (2025-2032).

The global amyloidosis therapeutics market is experiencing robust growth driven by the increasing prevalence and awareness of amyloidosis, along with significant advancements in clinical practices and diagnostic technologies. The rising acceptance of innovative and targeted therapies enhances the market landscape, generating demand for palliative care solutions. The aging population, particularly those with genetic predispositions, contributes to market expansion, supported by favorable government policies and orphan drug incentives that encourage the adoption of therapeutics. Enhanced awareness among healthcare professionals and patients facilitates the early identification of symptoms. Additionally, the integration of technologies such as AI, machine learning, IoT, and AR is revolutionizing drug discovery, precision medicine, patient monitoring, and diagnostic imaging, ultimately improving treatment outcomes and regulatory compliance in amyloidosis care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Amyloidosis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Amyloidosis Therapeutics Market Segments Analysis

Global Amyloidosis Therapeutics Market is segmented by Therapy Type, Route of Administration, Application, End User, Distribution Channel and region. Based on Therapy Type, the market is segmented into Chemotherapy, Stem Cell Transplantation, Targeted Therapy, Supportive Care & Surgery and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on Application, the market is segmented into AL Amyloidosis, ATTR Amyloidosis, AA Amyloidosis and Wild-Type ATTR. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Amyloidosis Therapeutics Market

The Global Amyloidosis Therapeutics market is significantly driven by the growing incidence of amyloidosis, attributed to heightened awareness and improved diagnostic techniques. This surge in understanding fosters a robust demand for therapeutics specifically targeting the condition. Additionally, the increasing adoption of innovative treatment options and advanced diagnostic methods is propelling market expansion, especially since amyloidosis is a rare disease that frequently remains undetected. Furthermore, enhanced healthcare reimbursement policies play a vital role in promoting both the diagnosis and treatment of amyloidosis, thereby further stimulating the market's growth and accessibility for affected patients.

Restraints in the Global Amyloidosis Therapeutics Market

The Global Amyloidosis Therapeutics market faces several challenges that hinder patient adoption and pharmaceutical investment. The substantial expenses associated with advanced medications, specialized treatments, and ongoing care create financial barriers for individuals seeking amyloidosis therapeutics. Additionally, the high costs involved in researching and developing innovative drugs, including RNA-based therapies, deter pharmaceutical companies from pursuing further exploration in this field. Furthermore, the rare and severe nature of amyloidosis, combined with its potential for fatal outcomes, leads many patients to be reluctant in embracing these therapies. Consequently, these factors collectively contribute to a constrained market environment for amyloidosis treatments.

Market Trends of the Global Amyloidosis Therapeutics Market

The Global Amyloidosis Therapeutics market is witnessing a significant trend towards the adoption of RNA-based therapies, driven by their heightened efficacy and cost-effectiveness. Patients increasingly favor these therapies as they address the root causes of the disease, providing long-term solutions with fewer doses required. Furthermore, the surge in research and development efforts coupled with innovative advancements from biotech firms and pharmaceutical companies is bolstering patient confidence in RNA-based treatments. This shift reflects a broader movement within the healthcare landscape towards more targeted and sustainable therapeutic options, positioning RNA-based therapies as a pivotal force in the market's evolution.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Amyloidosis Therapeutics Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Stem Cell Transplantation
• Targeted Therapy
• Supportive Care & Surgery
• Others

Global Amyloidosis Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous
• Subcutaneous

Global Amyloidosis Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• AL Amyloidosis
• ATTR Amyloidosis
• AA Amyloidosis
• Wild-Type ATTR

Global Amyloidosis Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Others

Global Amyloidosis Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online

Global Amyloidosis Therapeutics Market Size & CAGR (2025-2032)

• North America (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • US
  • Canada
• Europe (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Attralus (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caelum Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zentalis Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akcea Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations